The HEALEY ALS Platform trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with NEALS has successfully enrolled its first participants for the investigational product SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion).
The Neurological Clinical Research Institute at Massachusetts General Hospital is seeking individuals to participate in a Longitudinal Assessment of the Gut Microbiome in People with ALS research study currently enrolling under the direction of Dr. James Berry.
The Emory ALS Center is looking for adults who are 18 years and older who are at risk for getting diagnosed with C9 ALS in the future.
AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase II study for a promising new approach to treat amyotrophic lateral sclerosis (ALS).
